Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of β and ultimately cure β neurological diseases. Our pipeline includes programs for Alzheimerβs disease, amyotrophic lateral sclerosis (ALS), Parkinsonβs disease, and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; and Neurocrine Biosciences, Inc.. For more information, visit www.voyagertherapeutics.com.
Voyager Therapeutics is a registered trademark, and TRACER is a trademark, of Voyager Therapeutics, Inc.
The Novel Capsid Discovery team is generating a portfolio of designer AAV capsids with tailored properties using our state-of-the-art TRACER platform technology, which could prove truly transformative for the future of gene therapy.
We are looking for a talented and motivated Senior/Principal Research Associate to join the Vector Engineering group in order to support capsid programs aimed at improving tropism, tissue detargeting and immune evasion. The role will involve: 1) generating high-diversity AAV capsid libraries, 2) screening libraries using cell-based assays and/or in vivo models to select capsids with desired properties, 3) recovering nucleic acids from cells and animal tissues, 4) identifying capsid variants via Next-Generation Sequencing and analysis of large datasets, and 5) characterizing the functional properties of individual capsid variants.
As a Senior/Principal Research Associate in the Novel Capsid Discovery team, you will demonstrate a strong level of curiosity, self-motivation, and accountability as well as desire to drive research projects under minimal supervision. This is the opportunity to leverage cutting-edge technologies and make an impact in the field of AAV gene therapy by bringing novel capsids to the clinic.